Literature DB >> 20517178

Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients.

Carlos Muñoz-Santos1, Antonio Guilabert, Nemesio Moreno, Jordi To-Figueras, Celia Badenas, Esteve Darwich, Carmen Herrero.   

Abstract

Porphyria cutanea tarda is the most frequent porphyria and occurs in both sporadic and familial forms. We conducted the current study in a series of 152 consecutive patients with porphyria cutanea tarda attending the Porphyria Unit of the Hospital Clinic of Barcelona, Spain, to update the clinical manifestations of the disease and to study the sex differences, the proportion of familial forms, and the role of different risk factors in this population. Patients were classified as familial and sporadic cases according to erythrocyte uroporphyrinogen-decarboxylase activity and uroporphyrinogen-decarboxylase genotyping. In our cohort, skin fragility and blisters on the hands were the most frequent clinical manifestations. Women more frequently had facial hypertrichosis (84.8%; p = 0.004), affected areas other than the hands and face (33.3%; p = 0.008), and pruritus (27.3%; p = 0.041) compared with men. Of our patients, 11.8% did not present the typical clinical onset of the disease, with facial hypertrichosis and hyperpigmentation the more frequent complaints in these cases. Analysis of risk factors showed a high prevalence of hepatitis C virus infection (65.8%) and alcohol abuse (59.9%), both being more frequent in men (p < 0.001). Hepatitis C virus infection was the only risk factor that showed differences between the sporadic and familial forms in the logistic regression model (odds ratio, 0.05; 95% confidence interval, 0.006-0.46). In conclusion, atypical forms of presentation of porphyria cutanea tarda should be considered in order to prevent delayed diagnosis. We note the sustained role of hepatitis C virus infection in the precipitation of sporadic porphyria cutanea tarda. Therefore, in countries with a high prevalence of hepatitis C virus infection, the absence of such infection in a patient with porphyria cutanea tarda may suggest a possible familial case.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20517178     DOI: 10.1097/MD.0b013e3181d50928

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  7 in total

1.  CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.

Authors:  Jeffrey K Wickliffe; Sherif Z Abdel-Rahman; Chul Lee; Csilla Kormos-Hallberg; Gagan Sood; Catherine M Rondelli; James J Grady; Robert J Desnick; Karl E Anderson
Journal:  Mol Med       Date:  2010-10-15       Impact factor: 6.354

2.  A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda.

Authors:  J Andersen; E Gjengedal; S Sandberg; M Råheim
Journal:  Br J Dermatol       Date:  2014-11-27       Impact factor: 9.302

3.  Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ring.

Authors:  James C Barton; Corwin Q Edwards
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-02-17

4.  Porphyria Cutanea Tarda Presenting with Scleroderma, Ichthyosis, Alopecia, and Vitiligo.

Authors:  Megan E MacGillivray; Thomas G Salopek
Journal:  Case Rep Dermatol       Date:  2018-05-17

5.  Porphyria Cutanea Tarda Associated With Acute Hemorrhagic Pancreatitis.

Authors:  Manasi Singh; Ashley Duckett; Marc Heincelman
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

6.  Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.

Authors:  Carl Michael Baravelli; Sverre Sandberg; Aasne Karine Aarsand; Mette Christophersen Tollånes
Journal:  Orphanet J Rare Dis       Date:  2019-04-03       Impact factor: 4.123

7.  A case of Myhre syndrome mimicking juvenile scleroderma.

Authors:  Barbara Jensen; Rebecca James; Ying Hong; Ebun Omoyinmi; Clarissa Pilkington; Neil J Sebire; Kevin J Howell; Paul A Brogan; Despina Eleftheriou
Journal:  Pediatr Rheumatol Online J       Date:  2020-09-11       Impact factor: 3.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.